Cosmetic cross-reference

Isoleucine

CAS 73-32-5

Isoleucine (CAS 73-32-5) is a Phase 2 pharmaceutical compound with 1 bioactivity target and 3 adverse event associations.

SOURCE NLM DailyMed

Label records

SOURCE EMBL-EBI ChEMBL

Bioactivity

SOURCE DrugCentral

Adverse signals

SOURCE IUPHAR/BPS

PubMed IDs

SOURCE EMBL-EBI ChEMBL B25820EEF0F0

Compound Identity

Matched identifiers and naming fields for the pharmaceutical compound record.

Primary Name

Isoleucine

CAS Number

73-32-5

UNII

04Y7590D77

InChIKey

AGPKZVBTJJNPAG-WHFBIAKZSA-N

ChEMBL ID

CHEMBL1233584

Molecule Type

Small molecule

Source Match

EMBL-EBI ChEMBL (INCHIKEY)

Synonyms and normalized names

L-isoleucine

natural product

SOURCE EMBL-EBI ChEMBL B25820EEF0F0

Clinical Development Phase

Highest clinical development phase rendered from the matched compound identifier rows.

Phase 2

Mid-stage clinical development phase from the compound identifier source.

ChEMBL CHEMBL1233584 | Small molecule

SOURCE Ingredients table / CosIng profile same-CAS cross-reference

Cross-Reference to Cosmetics

Same-CAS ingredient record found in the cosmetics vertical.

This substance also has a cosmetic safety profile →

SOURCE EMBL-EBI ChEMBL 1 bioactivity row

Bioactivity & Target Interactions

Target-level activity records with assay counts, activity type, and measured value where present.

Target	Activity	Value	Assays	Organism
-	AC50	669.45 nM	2	-

SOURCE DrugCentral 3 associations

Adverse Event Associations

DrugCentral / FAERS disproportionality signal rows matched to this compound.

Reaction PT	Drug AE	LLR	MedDRA
Foetal growth restriction	15	72.625	10070531
Device related sepsis	10	51.617	10069802
Infantile apnoea	8	48.497	10077321

Association rows are source-linked signal records, not incidence rates or clinical causality claims.

SOURCE NLM RxNorm 4 name rows

Drug Names / RxNorm

Normalized drug-name vocabulary rows, RxCUIs, and source abbreviations.

Name	RxCUI	Type	Source
Isoleucine	6033	SU	MTHSPL
ISOLEUCINE	6033	SU	MTHSPL
isoleucine	6033	IN	RXNORM
L-isoleucine	6033	SY	RXNORM

SOURCE Rendered pharma page rows FAQPage JSON-LD

Frequently Asked Questions

Short answers generated only from the same visible source-linked rows on this page.

What is Isoleucine used for in pharmaceutical contexts?

Isoleucine (CAS 73-32-5) is rendered as a pharmaceutical compound from the matched source rows; no DailyMed product-name rows are present in this page query.

What are the known adverse events for Isoleucine?

Isoleucine has 3 DrugCentral/FAERS adverse event associations. Rendered reaction terms include Foetal growth restriction, Device related sepsis, Infantile apnoea. Signal rows are source-linked records and should not be read as incidence rates or causality conclusions.

Is Isoleucine also used in cosmetics?

Yes. The ingredients table has a same-CAS cosmetic profile for L-Isoleucine with EU status "permitted".

What clinical phase is Isoleucine in?

Isoleucine is rendered with ChEMBL max phase 2.